GOLDEN, Colo. — June 6, 2023 – PharmaJet® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery today announced that Marie Mazur, PharmD, has been appointed Chair of the Board of Directors. She replaces Ron Lowy who had chaired the Board since 2011.View
GOLDEN, Colo. — May 23, 2023 — PharmaJet®, a company engineering precision delivery systems that overcome the challenges of vaccine delivery, today announced their support for the World Health Organization’s (WHO) polio eradication campaigns in Pakistan starting in May 2023. PharmaJet is providing an additional 5 million syringes to theView
GOLDEN, Colo. — May 2, 2023 – PharmaJet ® a company engineering Precision Delivery Systems™ that may overcome the challenges of vaccines and pharmaceuticals delivery today announced that Nathalie Landry, has been appointed Chief Scientific Officer.View
PharmaJet announces U.S. Government award expansion to clinically assess a DNA Vaccine combined with its Systems.
GOLDEN, Colo. — April 18, 2023 —PharmaJet®, a company engineering Precision Delivery Systems™ (PDS) that overcome the challenges of vaccine delivery, today announced that it received a scope expansion and 3-year extension of its multi-year agreement with the Joint Science and Technology Office of the U.S. Defense Threat Reduction AgencyView
Needle-Free Precision Delivery Systems boost immune response of DNA vaccines: Comprehensive scientific literature review
GOLDEN, Colo. — April 4, 2023 — Results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods will be presented at the World Vaccine Congress 2023 on April 5, 2023 at 5:10 pm ET.View
PharmaJet partner Gennova Biopharmaceuticals seeks Emergency Use Authorization in India for the First Needle-free mRNA Vaccine Omicron Booster.
GOLDEN, Colo. — April 3, 2023 – Following completion of Phase II/III study, PharmaJet partner Gennova Biopharmaceuticals Limited has submitted data for its mRNA-based Omicron specific Covid-19 booster shot for Emergency Use Authorization (EUA) to the office of the drug controller General of India (DCGI). The submission corresponds with anView
PharmaJet announces clinical results from Scancell’s COVID-19 DNA vaccine study exclusively administered with their needle-free precision delivery systems.
GOLDEN, Colo. — March 21, 2023 — PharmaJet®, a company engineering precision delivery systems that may overcome the challenges of nucleic acid vaccine delivery, today announced that its partner, Scancell, a developer of novel immunotherapies for the treatment of cancer and infectious diseases, reported positive results from their Phase 1View
PharmaJet, Nigeria’s National Primary Health Care Development Agency and Health-focused Consortium Launch Assessment of the PharmaJet Tropis Vaccine Delivery System
GOLDEN, Colo. — March 7, 2023 — PharmaJet® , a company that engineers precision delivery systems that overcome the challenges of vaccine delivery, today announced the December 2022, in-country kickoff of a study to evaluate the impact of intradermal (ID) vaccine administration using their Tropis® ID Needle-free Injection System (NFIS).View
Review highlights growing evidence that PharmaJet’s precision delivery devices improve nucleic acid vaccine performance.
GOLDEN, Colo. — February 23, 2023 — In a review article recently published in Vaccines Journal (MDPI), Dr. Carmen Ledesma-Feliciano, Scientific Affairs Manager at PharmaJet, referencing over 25 studies, discusses multiple injection delivery methods including PharmaJet’s needle-free precision delivery systems, which enhance the clinical performance of DNA-based vaccines.View